IMMUNIZATIONTO RITUXIMAB IS MORE FREQUENT IN AUTOIMMUNE SYSTEMIC AUTOIMMUNE DISEASES THAN IN RHEUMATOID ARTHRITIS AND MAY BE MANAGED BY SWITCHING FROM RITUXIMAB TO OFATUMUMAB

被引：0
|
作者：
Combier, Alice [1 ]
Nocturne, Gaetane [1 ]
Henry, Julien [1 ]
Belkhir, Rakiba [1 ]
Pavy, Stephane [1 ]
Mariette, Xavier [1 ]
Seror, Raphaele [1 ]
机构：
[1] Bicetre Hosp, AP HP, Rheumatol, Le Kremlin Bicetre, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷
关键词：
D O I：
10.1136/annrheumdis-2019-eular.3343
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
AB0462
引用
收藏
页码：1695 / 1695
页数：1
相关论文
共 50 条
  • [21] Rituximab therapy for systemic vasculitis associated with rheumatoid arthritis: Results from the autoimmunity and rituximab registry
    Puechal, X.
    Gottenberg, J. E.
    Berthelot, J. M.
    Gossec, L.
    Meyer, O.
    Morel, J.
    Wendling, D.
    de Bandt, M.
    Houvenagel, E.
    Jamard, B.
    Lequerre, T.
    Morel, G.
    Richette, P.
    Sellam, J.
    Guillevin, L.
    Mariette, X.
    ARTHRITIS CARE & RESEARCH, 2012, 64 (03) : 331 - 339
  • [22] Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases
    Jens Vikse
    Kristin Jonsdottir
    Jan Terje Kvaløy
    Klaus Wildhagen
    Roald Omdal
    Rheumatology International, 2019, 39 : 1083 - 1090
  • [23] Tolerability and safety of long-term rituximab treatment in systemic inflammatory and autoimmune diseases
    Vikse, Jens
    Jonsdottir, Kristin
    Kvaloy, Jan Terje
    Wildhagen, Klaus
    Omdal, Roald
    RHEUMATOLOGY INTERNATIONAL, 2019, 39 (06) : 1083 - 1090
  • [24] Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab
    Heusele, Marion
    Clerson, Pierre
    Guery, Benoit
    Lambert, Marc
    Launay, David
    Lefevre, Guillaume
    Morell-Dubois, Sandrine
    Maillard, Helene
    Le Gouellec, Noemie
    Hatron, Pierre-Yves
    Hachulla, Eric
    CLINICAL RHEUMATOLOGY, 2014, 33 (06) : 799 - 805
  • [25] Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab
    Marion Heusele
    Pierre Clerson
    Benoit Guery
    Marc Lambert
    David Launay
    Guillaume Lefevre
    Sandrine Morell-Dubois
    Hélène Maillard
    Noémie Le Gouellec
    Pierre-Yves Hatron
    Eric Hachulla
    Clinical Rheumatology, 2014, 33 : 799 - 805
  • [26] RITUXIMAB IN SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES: ONE CENTER EXPERIENCE OF TREATMENT 515 PATIENTS
    Nasonov, E.
    Beketova, T.
    Ananyeva, L. P.
    Solovyev, S.
    Vasiliev, V.
    Koneva, O.
    Desinova, O.
    Palshina, S.
    Sokol, E.
    Nikollaeva, E.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1023 - 1023
  • [27] Perspectives of ofatumumab as CD20 targeted therapy in rheumatoid arthritis and other autoimmune diseases
    Pers, Yves Marie
    Jorgensen, Christian
    Immunotherapy, 2016, 8 (09) : 1091 - 1096
  • [28] EFFECTIVENESS AND SAFETY OF RITUXIMAB IN SYSTEMIC AUTOIMMUNE DISEASES: A CASE SERIES DESCRIBING THE EXPERIENCE OF AN AUTOIMMUNE DISEASES UNIT IN A 3-YEAR PERIOD
    Suarez, Milagros
    Argibay, Ana
    Portela, Clara
    Lima, Olalla
    Rodriguez Ferreira, Lorena Maria
    Estevez, Melania
    Maure, Brenda
    Vazquez Trinanes, Caritina
    Gimena, Beatriz
    Lorenzo, Rut
    Fernandez, Julian
    Rivera, Alberto
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1918 - 1919
  • [29] Autoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis
    Rose, Jonathan
    IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA, 2023, 43 (03) : 613 - 625
  • [30] Autoimmune Connective Tissue Diseases: Systemic Lupus Erythematosus and Rheumatoid Arthritis
    Rose, Jonathan
    EMERGENCY MEDICINE CLINICS OF NORTH AMERICA, 2022, 40 (01) : 179 - 191
12345